Anti-thyroid thioureylenes in the treatment of psoriasis

Medical Hypotheses

Volumn 62, Issue 3, 2004, Pages 431-437

  Elias, Alan N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; CYTOKINE; LIOTHYRONINE RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROPYLTHIOURACIL; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; THIAMAZOLE; VITAMIN D RECEPTOR;

BINDING SITE; CELL PROLIFERATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENETIC TRANSCRIPTION; HEALTH CARE COST; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; PSORIASIS; REVIEW;

EID: 1642302906     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.12.003     Document Type: Article

References (72)

1. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999;107: 595-605.
2. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995;332:581-8.
3. Fleischer Jr AB, Feldman SR, Rapp SR. Introduction. The magnitude of skin disease in the United States. Dermatol Clin 2000;18:xv-xxi.
4. Feldman SR, Fleischer Jr AB, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564-9.
5. Rapp SR, Feldman SR, Exum ML, Fleischer Jr AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
6. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46:850-60.
7. Barker JN. The pathophysiology of psoriasis. Lancet 1991;338:227-30.
8. Nickoloff BJ, Schroder JM, von den Driesch P, Raychaudhuri SP, Farber EM, Boehncke WH, et al. Is psoriasis a T-cell disease? Exp Dermatol 2000;9:359-75.
9. Nickoloff BJ, Wrone-Smith T. Superantigens, autoantigens, and pathogenic T cells in psoriasis. J Invest Dermatol 1998;110:459-60.
10. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol 1994;102:14S-8S.
11. Bowcock AM, Barker JN. Genetics of psoriasis: the potential impact on new therapies. J Am Acad Dermatol 2003;49:S51-56.
12. England RJ, Strachan DR, Knight LC. Streptococci tonsillitis and its association with psoriasis: a review. Clin Otolaryngol 1997;22:532-5.
13. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999;162:7480-91.
14. Cheng J, Tu Y, Li J, Huang C, Liu Z, Liu D. A study on the expression of interteukin (IL)-10 and IL-12 P35, P40 mRNA in the psoriatic lesions. J Tongji Med Univ 2001;21: 86-8.
15. Nestle FO, Nickoloff BJ. Dermal dendritic cells are important members of the skin immune system. Adv Exp Med Biol 1995;378:111-6.
16. de Rie MA. Interleukin 12 and psoriasis. Dermatology 1999;199:101.
17. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998;111:1053-7.
18. Asadullah K, Docke WD, Volk HD, Sterry W. The pathophysiological role of cytokines in psoriasis. Drugs Today (Barc) 1999;35:913-24.
19. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98: 1878-87.
20. Heenen M, Galand P. On cell kinetics in psoriasis. Br J Dermatol 1984;110:241-5.
21. Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickoloff BJ. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997;151: 1321-9.
22. Nickoloff BJ. Creation of psoriatic plaques: the ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint. J Cutan Pathol 2001;28:57-64.
23. Takahashi K, Aiba S, Uddin Z, Kasai H, Tagami H. Normal proliferative responses of peripheral blood mononuclear cells to streptococcal preparation OK-432 in patients with pustulosis palmaris et plantaris constitute a distinct feature from the reduced responses observed in those with psoriasis vulgaris, pustular psoriasis, and acrodermatitis continua of Hallopeau. J Dermatol Sci 2001;25: 87-92.
24. Wrone-Smith T, Johnson T, Nelson B, Boise LH, Thompson CB, Nunez G, et al. Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995;146:1079-88.
25. Kocak M, Bozdogan O, Erkek E, Atasoy P, Birol A. Examination of Bcl-2, Bcl-X and bax protein expression in psoriasis. Int J Dermatol 2003;42:789-93.
26. Takahashi H, Manabe A, Ishida-Yamamoto A, Hashimoto Y, Iizuka H. Aberrant expression of apoptosis-related molecules in psoriatic epidermis. J Dermatol Sci 2002;28: 187-97.
27. Kashiwai T, Hidaka Y, Takano T, Tatsumi KI, Izumi Y, Shimaoka Y, et al. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease. Endocr J 2003;50: 45-9.
28. Wilson R, McKillop JH, Chopra M, Thomson JA. The effect of antithyroid drugs on B and T cell activity in vitro. Clin Endocrinol (Oxf) 1988;28(4):389-97.
29. Hallengren B, Forsgren A, Melander A. Effects of antithyroid drugs on lymphocyte function in vitro. J Clin Endocrinol Metab 1980;51:298-301.
30. Weiss I, Davies TF. Inhibition of immunoglobulin-secreting cells by antithyroid drugs. J Clin Endocrinol Metab 1981; 53:1223-8.
31. Sharma BS, Elias AN. Effects of methimazole on human lymphocyte proliferation and natural killer cell activity. Gen Pharmacol 1987;18:449-53.
32. Weetman AP, Holt ME, Campbell AK, Hall R, McGregor AM. Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression. Br Med J (Clin Res Ed) 1984;288:518-20.
33. Weetman AP, Tandon N, Morgan BP. Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells. Lancet 1992;340:633-6.
34. Elias AN, Barr RJ. Low-dose oral propylthiouracil in the treatment of plaque psoriasis. Int J Dermatol 1995;34: 519-20.
35. Elias AN, Dangaran K, Barr RJ, Rohan MK, Goodman MM. A controlled trial of topical propylthiouracil in the treatment of patients with psoriasis. J Am Acad Dermatol 1994;31: 455-8.
36. Elias AN, Goodman MM, Liem WH, Barr RJ. Propylthiouracil in psoriasis: results of an open trial. J Am Acad Dermatol 1993;29:78-81.
37. Kose K, Utas S, Yazici C, Akdas A, Kelestimur F. Effect of propylthiouracil on adenosine deaminase activity and thyroid function in patients with psoriasis. Br J Dermatol 2001;144:1121-6.
38. Elias AN, Goodman MM, Rohan MK, Alpern K, Barr RJ. Methimazole (2-mercapto 1-methyl imidazole) in psoriasis - results of an open trial. Dermatology 1993;187: 26-9.
39. Utas S, Kose K, Yazici C, Akdas A, Kelestimur F. Antioxidant potential of propylthiouracil in patients with psoriasis. Clin Biochem 2002;35:241-6.
40. Elias AN, Goodman MM, Rohan MK. Serum ICAM-1 concentrations in patients with psoriasis treated with antithyroid thioureylenes. Clin Exp Dermatol 1993;18:526-9.
41. Elias AN, Goodman MM, Rohan MK. Effect of propylthiouracil and methimazole on serum levels of interteukin-2 receptors in patients with psoriasis. Int J Dermatol 1993;32:537-40.
42. Elias AN, Nanda VS, Barr RJ. Effect of therapy with oral propylthiouracil on serum interteukin-12 and interteukin-10 levels in patients with stable plaque psoriasis. Drugs Dermatol 2003.
43. Baadsgaard O, Fisher G, Voorhees JJ, Cooper KD. The role of the immune system in the pathogenesis of psoriasis. J Invest Dermatol 1990;95:32S-4S.
44. Sauder DN. The role of epidermal cytokines in inflammatory skin diseases. J Invest Dermatol 1990;95: 27S-8S.
45. Juhlin L, Hagforsen E, Juhlin C. Parathyroid hormone related protein is localized in the granular layer of normal skin and in the dermal infiltrates of mycosis fungoides but is absent in psoriatic lesions. Acta Derm Venereol 1992;72:81-3.
46. Tadini G, Cerri A, Crosti L, Cattoretti G, Berti E. P53 and oncogenes expression in psoriasis. Acta Derm Venereol Suppl (Stockh) 1989;146:33-5.
47. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
48. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990;17: 489-503.
49. Clevenger CV, Epstein AL, Bauer KD. Modulation of the nuclear antigen p105 as a function of cell-cycle progression. J Cell Physiol 1987;130:336-43.
50. Bolton WE, Mikulka WR, Healy CG, Schmittling RJ, Kenyon NS. Expression of proliferation associated antigens in the cell cycle of synchronized mammalian cells. Cytometry 1992;13:117-26.
51. Takasaki Y, Deng JS, Tan EM. A nuclear antigen associated with cell proliferation and blast transformation. J Exp Med 1981;154:1899-909.
52. Prelich G, Tan CK, Kostura M, Mathews MB, So AG, Downey KM, et al. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature 1987;326: 517-20.
53. Knudson Jr AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-43.
54. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
55. Kern SE, Kinzler KW, Baker SJ, Nigro JM, Rotter V, Levine AJ, et al. Mutant p53 proteins bind DNA abnormally in vitro. Oncogene 1991;6:131-6.
56. Elias AN, Barr RJ, Rohan MK, Dangaran K. Effect of orally administered antithyroid thioureylenes on PCNA and P53 expression in psorlatic lesions. Int J Dermatol 1995;34:280-3.
57. Elias AN, Barr RJ, Nanda VS. p16 expression in psoriatic lesions following therapy with propylthiouracil an antithyroid thioureylene. Int J Dermatol 2003.
58. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/AP01 contains a sequence motif related to the death domain. J Biol Chem 1995;270: 7795-8.
59. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-12.
60. Chinnaiyan AM, Dixit VM. Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. Semin Immunol 1997;9:69-76.
61. Oppenheimer JH. Thyroid hormone action at the nuclear level. Ann Intern Med 1985;102:374-84.
62. Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM. The c-erb-A gene encodes a thyroid hormone receptor. Nature 1986;324:641-6.
63. Nakai A, Seino S, Sakurai A, Szilak I, Bell GI, DeGroot LJ. Characterization of a thyroid hormone receptor expressed in human kidney and other tissues. Proc Natl Acad Sci USA 1988;85:2781-5.
64. Evans RM, Hollenberg SM. Zinc fingers: gilt by association. Cell 1988;52:1-3.
65. Carson-Jurica MA, Schrader WT, O'Malley BW. Steroid receptor family: structure and functions. Endocr Rev 1990;11:201-20.
66. Yu VC, Delsert C, Andersen B, Holloway JM, Devary OV, Naar AM, et al. RXR beta: a coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell 1991;67:1251-66.
67. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992;355:446-9.
68. Zhang XK, Lehmann J, Hoffmann B, Dawson MI, Cameron J, Graupner G, et al. Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 1992;358:587-91.
69. Takagi S, Hummel BC, Walfish PG. Thionamides and arsenite inhibit specific T3 binding to the hepatic nuclear receptor. Biochem Cell Biol 1990;68:616-21.
70. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377:454-7.
71. Hortein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995;377:397-404.
72. Zamir I, Harding HP, Atkins GB, Horlein A, Glass CK, Rosenfeld MG, et al. A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol Cell Biol 1996;16:5458-65.